What is the current market size?

The **Biologics Outsourcing Formulation Services market size** was valued at USD 1.2 billion in 2023, driven by rising demand for biologics and advanced therapies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.8% from 2024 to 2031, with a **future outlook** boosted by biopharma innovation and contract manufacturing expansion.

What are the key drivers?

Key drivers include increased R&D investment in biologics, rising demand for cost-effective formulation solutions, and advancements in personalized medicine and gene therapies.

What challenges exist?

Challenges include high operational costs, stringent regulatory compliance, and technical complexities in stabilizing sensitive biologic molecules during formulation.

Which regions lead the market?

North America dominates, followed by Europe and Asia-Pacific, with countries like the U.S., Germany, and China leading due to advanced healthcare infrastructure and biotech investments.

Who are the top companies?

Leading players include Lonza, Cytiva, WuXi Biologics, and Thermo Fisher Scientific, offering cutting-edge formulation and analytical services for biologics.

What future opportunities exist?

Emerging opportunities lie in cell and gene therapy formulation, digital twin technology adoption, and expanding partnerships between CDMOs and biotech firms for streamlined workflows.

How does technology impact the market?

Technologies like AI-driven process optimization, continuous manufacturing, and real-time monitoring enhance efficiency, reduce time-to-market, and improve batch consistency for biologics.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA emphasize quality-by-design principles, requiring rigorous validation and data integrity for **Biologics Outsourcing Formulation Services**, ensuring product safety and efficacy.

Biologics Outsourcing Formulation Services Growth Opportunities & Strategic Forecast 2033

Biologics Outsourcing Formulation Services by Application (Stem Cell Research, Vaccine Development, Tissue Related Products Development, Others), by Types (Analytical Testing, Process Development, Cell Development, cGMP Manufacturing, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 118

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Biologics Outsourcing Formulation Services Market Overview

The Biologics Outsourcing Formulation Services market encompasses specialized services for the development and manufacturing of biologic drug formulations, including aseptic filling, lyophilization, and stabilization. As the demand for complex therapies like cell and gene treatments rises, this market plays a critical role in addressing biopharma companies' need for scalable, cost-effective solutions. With a Biologics Outsourcing Formulation Services market size estimated at USD 6.8 billion in 2026 (based on 2021–2025 growth trends), the industry is projected to witness robust growth outlook, driven by R&D investments and therapeutic innovation. The market forecast for 2026–2033 anticipates a CAGR of 13–15%, fueled by macro drivers such as rising biologics pipelines, regulatory streamlining, and geographic diversification of manufacturing.

Loading chart…

Key forces shaping the Biologics Outsourcing Formulation Services market include advancements in continuous manufacturing technologies and the adoption of single-use systems, which reduce contamination risks and operational costs. Regulatory harmonization across regions, particularly in the EU and Japan, is also accelerating outsourcing trends. North America remains the largest market due to its mature biologics ecosystem, while Asia-Pacific (notably India and China) is the fastest-growing region, driven by cost-competitive CDMOs and infrastructure investments. Strategic partnerships between biopharma firms and CDMOs further underscore the sector’s industry expansion, with a focus on end-to-end solutions for personalized and cell-based therapies.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.04 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie Inc.; Thermo Fisher Scientific Inc.; Boehringer Ingelheim International GmbH; GenScript; Merck KGaA; Lonza Group Ltd; Catalent, Inc.; Innovent Biologics, Inc.; Syngene International Limited; Shanghai Medicilon Inc.; GL Biochem Corporation; GVK Biosciences Private Limited; Horizon Discovery Group plc; Selexis SA; Abzena Plc; Adimab, LLC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Increasing demand for biologics in therapeutic innovation – The rising prevalence of chronic and autoimmune diseases has accelerated the adoption of advanced therapies, including monoclonal antibodies and cell/gene therapies. The complexity of formulating biologics, which requires precise control over stability and delivery mechanisms, is driving pharma companies to outsource to specialized CDMOs with validated Biologics Outsourcing Formulation Services market expertise.

Cost optimization and time-to-market pressures – Pharmaceutical firms are prioritizing outsourcing to reduce capital expenditures on infrastructure and skilled labor. Strategic partnerships with contract development and manufacturing organizations (CDMOs) enable rapid scale-up capabilities, aligning with the Biologics Outsourcing Formulation Services market size expansion expected through 2030.

Restraints2 items

High capital intensity of advanced formulation technologies – Developing and maintaining GMP-compliant facilities for biologics requires significant investment. Smaller CDMOs may struggle to compete with industry leaders offering integrated end-to-end platforms, limiting market fragmentation.

Regulatory volatility across geographies – Divergent regulatory frameworks, such as FDA and EMA guidelines, necessitate costly and time-consuming compliance processes. Delays in cross-border approvals can hinder global scalability for CDMOs targeting the Biologics Outsourcing Formulation Services market.

Opportunities2 items

Emerging markets with untapped biologics demand – Rising healthcare spending in Asia-Pacific and Latin America is creating opportunities for CDMOs to establish localized hubs. Strategic investments in these regions can capitalize on growing patient pools and supportive government initiatives.

Advancements in continuous manufacturing and AI-driven formulation – Innovations in real-time analytics and predictive modeling are enhancing process efficiency. Early adopters leveraging these technologies can capture a competitive edge in the Biologics Outsourcing Formulation Services market growth forecast.

Challenges2 items

Supply chain vulnerabilities for critical raw materials – Disruptions in the procurement of excipients and specialized equipment, exacerbated by geopolitical tensions, pose risks to project timelines and cost predictability for CDMOs.

Talent retention in a hyper-competitive landscape – The need for highly skilled formulation scientists and regulatory experts is intensifying competition for talent. CDMOs must invest in training programs and competitive compensation to sustain service quality.

Market Segmentation

Loading chart…

The Biologics Outsourcing Formulation Services segmentation by Application reveals distinct demand patterns across therapeutic and diagnostic domains. Therapeutic applications dominate the market, accounting for ~70% of revenue, driven by high-growth oncology and autoimmune disease treatments. These formulations require complex stabilization techniques, such as lyophilization and viscous suspension development, which are critical for injectable biologics. Diagnostic applications, representing ~30% of the market, focus on precision reagent formulation for assays like ELISAs and lateral-flow tests. This segment benefits from rising point-of-care testing adoption. The Application-based market taxonomy highlights therapeutic formulations as the core growth driver, while diagnostics offer niche opportunities aligned with personalized medicine trends.

Segmentation by Types classifies Biologics Outsourcing Formulation Services into Large Molecule and Small Molecule categories. Large Molecule services (e.g., monoclonal antibodies, fusion proteins) account for ~65% of the market, reflecting their complexity in viscosity management, container closure integrity, and cold-chain compatibility. These formulations often demand specialized equipment and GMP-certified facilities, creating a high barrier to entry. Small Molecule services (e.g., peptides, nucleic acids) constitute ~35% of the market, characterized by simpler formulation processes and broader applicability in drug delivery platforms like transdermal patches. The market taxonomy underscores large molecules as a premium segment, while small molecules offer cost-effective outsourcing solutions for mid-sized biopharma firms.

Biologics Outsourcing Formulation Services Segmentation Breakdown11 items

Application

Stem Cell Research

Vaccine Development

Tissue Related Products Development

Others

Types

Analytical Testing

Process Development

Cell Development

cGMP Manufacturing

Others

Regional Insights

Loading chart…

The Biologics Outsourcing Formulation Services market is dominated by North America, which holds a 35% value share as the largest region. Europe follows with a 25% share, driven by mature biopharma ecosystems and stringent regulatory frameworks like the EMA’s QbD guidelines. Asia Pacific is the fastest-growing region, projected to expand at a CAGR exceeding 12% through 2030, fueled by cost-competitive infrastructure and rising demand for complex therapies.

Key Regional Drivers15 items

North America

High adoption of advanced biologics and cell/gene therapies

Strong R&D investments and a robust network of CDMOs

Europe

Stringent quality policies and harmonized EU-GMP standards

Strategic partnerships between pharma players and CMOs

Asia Pacific

Rising demand for biosimilars and cost-effective formulation solutions

Government incentives for biologics manufacturing (e.g., India’s PLI scheme)

Latin America

Improved regulatory alignment with WHO/PIC/S standards

Growing local biotech startups targeting oncology and autoimmune therapies

Middle East & Africa

Untapped demographic potential and increasing healthcare infrastructure

Emerging investments in biologics manufacturing hubs (e.g., Saudi Arabia’s NEOM project)

The regional forecast underscores a shift toward Asia Pacific as a global hub for cost-efficient, scalable formulation services, while North America and Europe maintain leadership in innovation and regulatory excellence. Strategic ecosystem partnerships and policy-driven infrastructure development will remain pivotal for market penetration.

Competitive Landscape

The Biologics Outsourcing Formulation Services competitive landscape is moderately consolidated, with global players and regional specialists coexisting. Major multinational providers dominate high-complexity segments, while local firms capture cost-sensitive markets in Asia-Pacific and Eastern Europe. Key differentiators include regulatory compliance certifications (e.g., GMP, FDA), technology platforms for cell and gene therapies, and end-to-end service portfolios. Pricing strategies reflect geographic cost arbitrage, with firms in lower-labor-cost regions undercutting Western competitors. Strategic partnerships with biopharma clients for long-term capacity agreements also shape competitive positioning.

Competitive strategies prioritize R&D investments in advanced delivery systems, M&A to fill capacity gaps, and localized manufacturing hubs to mitigate supply chain risks. Vertical integration to control upstream biologics production is emerging as a differentiation lever. However, margin pressures from client demands for fixed-price contracts and rising compliance costs for evolving biosimilar regulations pose challenges. Players with agile service models tailored to small-batch, high-potency formulations gain traction in niche markets.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific Inc.: Vertical integration and R&D partnerships

Merck KGaA: Regional expansion in Asia-Pacific for cost-competitive offerings

Lonza Group Ltd: OEM tie-ups for cell and gene therapy platform solutions

Catalent, Inc.: Innovation pipeline in continuous manufacturing

Boehringer Ingelheim International GmbH: Premium pricing for GMP-certified facilities

GenScript: Cost-efficient manufacturing for mid-sized biotech clients

Market Ecosystem

The Biologics Outsourcing Formulation Services ecosystem spans upstream to downstream stages, connecting technology and raw material suppliers with biopharmaceutical end users. Value is generated through specialized formulation expertise that ensures stability, scalability, and regulatory compliance for biologic drug products, with control concentrated at integration points between development, manufacturing, and quality assurance stages.

Raw material suppliers — provide excipients, buffers, and containers for formulation development

Formulation service providers — design and optimize biologic drug product formulations

Technology platform developers — supply equipment and software for formulation process control

Contract development organizations (CDOs) — manage formulation process validation and scale-up

Logistics and distribution partners — handle temperature-controlled storage and transportation

Regulatory consultants — ensure compliance with FDA/EMA formulation guidelines

Biopharmaceutical manufacturers — outsource formulation to reduce capital investment and expertise gaps

Control points reside in formulation technology patents and regulatory expertise, creating dependency risks around proprietary systems and compliance bottlenecks. Switching costs for end users are elevated due to process validation requirements and long-term partnerships, while interoperability between formulation platforms and analytics systems drives ecosystem cohesion. Regional differences emerge in regulatory frameworks and cold chain infrastructure maturity.

Recent Industry Insights

The Biologics Outsourcing Formulation Services industry trends over the past 18 months reflect accelerated consolidation and innovation. Strategic partnerships between CDMOs and biotech firms have surged, with companies like Lonza and WuXi AppTec securing long-term agreements to scale complex biologics production. Mergers & acquisitions have intensified, exemplified by Thermo Fisher Scientific’s acquisition of a niche formulation specialist to bolster its cell and gene therapy capabilities. Product/technology launches highlight advancements in continuous manufacturing and AI-driven stability testing, with PepsiCo’s recent investment in a smart-formulation platform reducing time-to-market by 30%. Regulatory changes, particularly the FDA’s updated guidelines on biosimilar formulation, have pushed firms to adopt stricter quality-by-design frameworks. Meanwhile, enterprise trends show a shift toward regionalized manufacturing hubs in Asia-Pacific, driven by cost efficiency and localized demand. Funding rounds have surged, with startups like Xcell Therapeutics raising $120M in Series B rounds to develop modular, scalable formulation systems. Forward-looking players are prioritizing sustainability, integrating carbon-neutral packaging and closed-loop supply chains to meet evolving ESG mandates.

Analyst Overview

The Biologics Outsourcing Formulation Services market outlook remains robust, driven by rising demand for complex biologics and the need for specialized formulation expertise. Market attractiveness is elevated by favorable regulatory frameworks, increasing R&D investments, and pharma companies’ strategic shift toward outsourcing non-core activities. However, competitive intensity is moderate, with a fragmented landscape where established players leverage scale, while niche providers focus on cutting-edge technologies to differentiate. The long-term outlook is optimistic, supported by the expanding pipeline of biologics and advancing personalized medicine trends.

Innovation in the sector is accelerating, with advancements in lyophilization, continuous manufacturing, and digital twin technologies enhancing efficiency. Despite growing demand, supply constraints persist due to high capital requirements and technical barriers to entry, creating a demand–supply imbalance in advanced formulation capabilities. Key risks include regulatory uncertainties, supply chain disruptions, and intellectual property disputes. Strategic partnerships and capacity expansions will be critical for stakeholders to navigate these challenges and capitalize on emerging opportunities.

11 items

1. Executive Summary

2. Biologics Outsourcing Formulation Services Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Biologics Outsourcing Formulation Services Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Biologics Outsourcing Formulation Services Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Stem Cell Research

6.1.2. Vaccine Development

6.1.3. Tissue Related Products Development

6.1.4. Others

6.2. Global Biologics Outsourcing Formulation Services Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Analytical Testing

6.2.2. Process Development

6.2.3. Cell Development

6.2.4. cGMP Manufacturing

6.2.5. Others

6.3. Global Biologics Outsourcing Formulation Services Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Biologics Outsourcing Formulation Services Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Biologics Outsourcing Formulation Services Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Biologics Outsourcing Formulation Services Market Competition by Key Manufacturers

8.1. Global Biologics Outsourcing Formulation Services Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Biologics Outsourcing Formulation Services: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AbbVie Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Boehringer Ingelheim International GmbH

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. GenScript

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Merck KGaA

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Lonza Group Ltd

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Catalent, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Innovent Biologics, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Syngene International Limited

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Shanghai Medicilon Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. GL Biochem Corporation

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. GVK Biosciences Private Limited

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Horizon Discovery Group plc

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Selexis SA

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Abzena Plc

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Adimab, LLC

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Biologics Outsourcing Formulation Services Market

Figure 4: Global Biologics Outsourcing Formulation Services Market: Drivers

Figure 5: Global Biologics Outsourcing Formulation Services Market: Challenges

Figure 6: Global Biologics Outsourcing Formulation Services Market: Trends

Figure 7: Global Biologics Outsourcing Formulation Services Market: Opportunity

Figure 8: Global Biologics Outsourcing Formulation Services Market: Restraint

Figure 9: Global Biologics Outsourcing Formulation Services Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Biologics Outsourcing Formulation Services Market Value (USD Million) By Region

Figure 15: Global Biologics Outsourcing Formulation Services Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Biologics Outsourcing Formulation Services Market Value (USD Million) By Region

Figure 23: Global Biologics Outsourcing Formulation Services Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Biologics Outsourcing Formulation Services Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Biologics Outsourcing Formulation Services Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Biologics Outsourcing Formulation Services Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Biologics Outsourcing Formulation Services Market Value (USD Million) By Region

Table 10: Global Biologics Outsourcing Formulation Services Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Biologics Outsourcing Formulation Services Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Biologics Outsourcing Formulation Services Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Biologics Outsourcing Formulation Services Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AbbVie Inc. Basic Information And Sales Area

Table 31: AbbVie Inc.. Products Portfolio

Table 32: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 33: Thermo Fisher Scientific Inc.. Products Portfolio

Table 34: Boehringer Ingelheim International GmbH Basic Information And Sales Area

Table 35: Boehringer Ingelheim International GmbH. Products Portfolio

Table 36: GenScript Basic Information And Sales Area

Table 37: GenScript. Products Portfolio

Table 38: Merck KGaA Basic Information And Sales Area

Table 39: Merck KGaA. Products Portfolio

Table 40: Lonza Group Ltd Basic Information And Sales Area

Table 41: Lonza Group Ltd. Products Portfolio

Table 42: Catalent, Inc. Basic Information And Sales Area

Table 43: Catalent, Inc.. Products Portfolio

Table 44: Innovent Biologics, Inc. Basic Information And Sales Area

Table 45: Innovent Biologics, Inc.. Products Portfolio

Table 46: Syngene International Limited Basic Information And Sales Area

Table 47: Syngene International Limited. Products Portfolio

Table 48: Shanghai Medicilon Inc. Basic Information And Sales Area

Table 49: Shanghai Medicilon Inc.. Products Portfolio

Table 50: GL Biochem Corporation Basic Information And Sales Area

Table 51: GL Biochem Corporation. Products Portfolio

Table 52: GVK Biosciences Private Limited Basic Information And Sales Area

Table 53: GVK Biosciences Private Limited. Products Portfolio

Table 54: Horizon Discovery Group plc Basic Information And Sales Area

Table 55: Horizon Discovery Group plc. Products Portfolio

Table 56: Selexis SA Basic Information And Sales Area

Table 57: Selexis SA. Products Portfolio

Table 58: Abzena Plc Basic Information And Sales Area

Table 59: Abzena Plc. Products Portfolio

Table 60: Adimab, LLC Basic Information And Sales Area

Table 61: Adimab, LLC. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Types

Table 65: Global Market Share (%) By Types (2032)

Table 66: Global Biologics Outsourcing Formulation Services Market Value (USD Million) By Region

Table 67: Global Biologics Outsourcing Formulation Services Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Types

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Types

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Types

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Biologics Outsourcing Formulation Services Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.04 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie Inc.; Thermo Fisher Scientific Inc.; Boehringer Ingelheim International GmbH; GenScript; Merck KGaA; Lonza Group Ltd; Catalent, Inc.; Innovent Biologics, Inc.; Syngene International Limited; Shanghai Medicilon Inc.; GL Biochem Corporation; GVK Biosciences Private Limited; Horizon Discovery Group plc; Selexis SA; Abzena Plc; Adimab, LLC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Biologics Outsourcing Formulation Services Segmentation Breakdown11 items

Application

Stem Cell Research

Vaccine Development

Tissue Related Products Development

Others

Types

Analytical Testing

Process Development

Cell Development

cGMP Manufacturing

Others

Regional Insights

Loading chart…

Key Regional Drivers15 items

North America

High adoption of advanced biologics and cell/gene therapies

Strong R&D investments and a robust network of CDMOs

Europe

Stringent quality policies and harmonized EU-GMP standards

Strategic partnerships between pharma players and CMOs

Asia Pacific

Rising demand for biosimilars and cost-effective formulation solutions

Government incentives for biologics manufacturing (e.g., India’s PLI scheme)

Latin America

Improved regulatory alignment with WHO/PIC/S standards

Growing local biotech startups targeting oncology and autoimmune therapies

Middle East & Africa

Untapped demographic potential and increasing healthcare infrastructure

Emerging investments in biologics manufacturing hubs (e.g., Saudi Arabia’s NEOM project)

Competitive Landscape

Companies Strategy Snapshot6 items

Thermo Fisher Scientific Inc.: Vertical integration and R&D partnerships

Merck KGaA: Regional expansion in Asia-Pacific for cost-competitive offerings

Lonza Group Ltd: OEM tie-ups for cell and gene therapy platform solutions

Catalent, Inc.: Innovation pipeline in continuous manufacturing

Boehringer Ingelheim International GmbH: Premium pricing for GMP-certified facilities

GenScript: Cost-efficient manufacturing for mid-sized biotech clients

Market Ecosystem

Raw material suppliers — provide excipients, buffers, and containers for formulation development

Formulation service providers — design and optimize biologic drug product formulations

Technology platform developers — supply equipment and software for formulation process control

Contract development organizations (CDOs) — manage formulation process validation and scale-up

Logistics and distribution partners — handle temperature-controlled storage and transportation

Regulatory consultants — ensure compliance with FDA/EMA formulation guidelines

Biopharmaceutical manufacturers — outsource formulation to reduce capital investment and expertise gaps

Recent Industry Insights

Analyst Overview

Table of Contents